Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
29/04/2024 12:57
April 29 (Reuters) - Mosaic Immunoengineering Inc
CPMV.PK :
* ONCOTELIC THERAPEUTICS, INC. TO SELL ITS NECROPTOSIS
CANCER
THERAPY ASSETS TO MOSAIC IMMUNOENGINEERING, INC.
Source text for Eikon: ID:nGNX8BSQkc
Further company coverage: CPMV.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas